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There are many lessons speciﬁ cally related to Polish situation (middle sized – 38 mln
inhabitants -European country) but among them some examples can be shared. Settle-
ment organization related to HTA development and support it in self-governed elabo-
rating of assessment and appraisal procedure is one of most important example in our 
opinion. Another is related to international collaboration and many dimensions of it
such as exchanging experience, consulting ideas, sharing knowledge or support in 
training staff.
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ORGANIZATION: The Pharmacy and Therapeutic Committee of the Veneto Region,
Italy, is a regulating body responsible for the deﬁ nition of the Regional Hospital For-
mulary in Veneto. Veneto comprised a territory of 4.800.000 inhabitants in the north-
east part of Italy. The Unit for the Evaluation of Drug Efﬁ cacy (Unità di Valutazione 
dell’Efﬁ cacia del Farmaco, UVEF) is the technical group responsible for the evaluation 
reports of new drugs to be submitted to the Committee. The Committee evaluates the
introduction of new technologies based on relevant information from the literature 
regarding: efﬁ cacy, safety and cost. Cost data are based on the acquisition cost of the 
new drugs and the alternatives already included in the formulary. The HTA reports 
contain the following relevant sections: general information; alternative treatments 
and insights from existing guidelines; efﬁ cacy and safety data; other HTA reports;
pharmacoeconomics data from the literature; comparative drug costs. PROBLEM OR 
ISSUE ADDRESSED: In 2008, four new indications for bevacizumab were approved 
by the National Drug Agency: 1) metastatic colon-rectal cancer in association with 
ﬂ uoropirimidines; 2) in combination with interferon alfa-2a for the ﬁ rst line treatment 
of patients with advanced and/or metastatic renal cell cancer; 3) in combination with 
paclitaxel as ﬁ rst line treatment in metastatic breast cancer; 4) in addition to platinum-
based chemotherapy for the ﬁ rst-line treatment of patients with unresectable advanced, 
metastatic or recurrent non-small-cell lung cancer (other than predominantly squa-
mous cell histology). Due to rising cost for oncological drugs in the region (total 
expenditure for 2007 Euro 151.001.736), the Committee put particular attention to 
the introduction of new oncological drugs in the formulary. GOALS: as in all the 
evaluations made by the committee, the goal was to perform an evaluation process 
taking into account all the relevant information on efﬁ cacy, safety and costs data, in 
order to include in the formulary the indications with a favourable beneﬁ t/risk and 
beneﬁ t/cost proﬁ le. OUTCOMES ITEMS USED IN THE DECISION: The following 
information were part of the evaluation: efﬁ cacy data from main clinical trials (phase 
II and III), published in full and reported in the EMEA assessment report; safety data
from the same sources; considerations on safety, efﬁ cacy and cost by the main regula-
tory and HTA agencies in Europe (e.g., Scottish Medicine Consortium, NICE, HAS 
France); relevant organizational and cost issues arising from published pharmacoeco-
nomic studies, when applicable; comparative drug costs in relation with alternatives
already present in the regional formulary. IMPLEMENTATION STRATEGY: based 
on the produced evaluations, the following were the considerations that brought to 
the Committee’s decisions: 1) metastatic colon-rectal cancer: efﬁ cacy data on second-
line treatment demonstrate a signiﬁ cant improvement in median overall and disease 
free survival; efﬁ cacy data on ﬁ rst-line treatment were less robust, with an increase in 
disease free survival of one month. In the last case the Committee did not include the
drug in the formulary 2) renal cancer: the Committee considered the unfavourable 
safety proﬁ le of the drug, the less accepted route of administration (ev instead than 
oral sunitinib in ﬁ rst line treatment and sorafenib in second line), the need of a con-
comitant administration of interferon; the higher cost of the new regimen. Based on 
these factors, the Committee did not include the new indication in the formulary 3) 
breast cancer: based on the efﬁ cacy data, which demonstrated almost a double pro-
gression free survival, and a strict correlation between progression free survival and 
overall survival, the Committee approved the indication 4) non small cell lung cancer:
the Commission analized the efﬁ cacy data and pointed out that the positive results 
were obtained in association with carboplatin and paclitaxel. The indication was
included in the formulary with a limitation in association with these two drugs.
RESULTS: these decisions have been implemented and hospitals in the region are
actually using the drug according to the restrictions. In parallel, a national registry by 
the Italian Regulatory Agency on Drugs had been set up. From the registry, it will be 
possible to perform a qualitative analysis on the usage, and on the indications and 
patient’s outcomes. LESSONS LEARNED: In the evaluation process, the decision is
mainly taken based on the results on efﬁ cacy and safety from the published clinical
trials. Other countries regulatory agencies opinions are considered, while published 
cost effectiveness data conducted in different settings are often useless for taking deci-
sions at local level, due to lack of transferability of the chosen models and/or the dif-
ferent cost and organizational data.
